Posted by Michael Wonder on 16 Jan 2026
Santhera receives Swissmedic approval of Agamree (vamorolone) for the treatment of Duchenne muscular dystrophy
15 January 2026 - Commercial launch in Switzerland anticipated in H2, 2026.
Santhera Pharmaceuticals announces that the Swiss Agency for Therapeutic Products (Swissmedic), has approved Agamree (vamorolone) for the treatment of Duchenne muscular dystrophy in patients four years of age and older.
